Immuneering Names Andrew Gengos Chief Financial Officer
Dow Jones19:53
By Colin Kellaher
Immuneering has hired Andrew Gengos as the late-stage clinical oncology company's new chief financial officer.
Immuneering on Monday said Gengos most recently served as finance chief and head of corporate development at Terns Pharmaceuticals, which Merck & Co. acquired last month.
Mallory Morales, Immuneering's senior vice president of finance, chief accounting officer and treasurer, has been serving as the Cambridge, Mass., company's principal financial and accounting officer.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 15, 2026 07:53 ET (11:53 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments